Trial Profile
A Prospective Study Evaluating the Safety and Effectiveness of EVARREST® Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open, Abdominal, Retroperitoneal, Pelvic and Thoracic (non-cardiac) Surgery in Pediatric Patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Fibrin (Primary) ; Fibrin (Primary)
- Indications Surgical blood loss
- Focus Therapeutic Use
- Sponsors Ethicon
- 22 Feb 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2025.
- 22 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2025.
- 23 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.